TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502) Net Margin Improvement Tests Bearish Profitability Narratives
Takeda Pharmaceutical (TSE:4502) has reported its FY 2026 results with fourth quarter revenue of ¥1.1t and a basic EPS loss of ¥15.40, while trailing 12 month revenue stands at ¥4.5t and basic EPS at ¥121.75. Over recent periods, quarterly revenue has moved within a tight band between about ¥1.1t and ¥1.2t. Basic EPS has ranged from a loss of ¥65.22 to a profit of ¥79.40, as one off items and underlying earnings pulled results in different directions. For investors, a key focus is how these...